

INDGN/SE/2026-27/07

April 29, 2026

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051, India. Trading symbol: INDGN
---	---

Dear Sir / Madam,

Sub: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the copy of Press Release dated April 29, 2026, titled "Indegene Reports 32.8% YoY Growth in Q4FY26, Crosses ₹1,000 Crore Quarterly Revenue and ₹3,500 Crore Annual Revenue Milestone".

This will also be posted on the company's website at <https://www.indegene.com/>

Kindly take the same on records.

Thanking you,

Yours Sincerely,

For Indegene Limited

Srishti Ramesh Kaushik
Company Secretary and Compliance Officer

Encl: As above



Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy
Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru-
560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777
www.indegene.com

CIN: L73100KA1998PLC102040

Press release

Indegene Reports 32.8% YoY Growth in Q4FY26, Crosses ₹1,000 Crore Quarterly Revenue and ₹3,500 Crore Annual Revenue Milestone

Bengaluru, India, April 29, 2026: Indegene, the strategic operating partner to the global life sciences industry, reported its financial results for Q4 and the full year ended March 31, 2026.

Q4 FY26 Highlights

- **Revenue** of INR 10,034 Mn (USD 109.7 Mn), up **32.8% YoY** in INR (**25.6% YoY** in USD) & **6.5% QoQ**
- **Adjusted EBITDA** of INR 1,889 Mn at **18.8%** margin, up **23.2% YoY & 5.4% QoQ**
- **Strong bookings quarter:** 1 deal >\$3M ACV and 7 deals in the \$1–3M range

Full-Year FY26 Highlights

- **Revenue** of INR 35,105 Mn (USD 396.9 Mn), up **23.6% YoY** in INR (**18.2%** in USD)
- **Adjusted EBITDA** of INR 6,793 Mn at 19.4% margin, up **20.8% YoY**
- **Cash flow from operations** of INR 6,508 Mn, up **47.3% YoY**, highlighting the strength of business and operating fundamentals
- Board has recommended a final dividend of **INR 2.25** per equity share for FY26, up **12.5% YoY**

Sl. No.	Particulars	Quarter ended			Year ended	
		Mar 31, 2026	Dec 31, 2025	Mar 31, 2025	Mar 31, 2026	Mar 31, 2025
1.	Revenue from operations	10,034	9,421	7,556	35,105	28,393
2.	Revenue from operations (\$ Mn)	109.7	106.1	87.4	396.9	335.7
3.	YoY revenue growth from operations (%)	32.8%	30.8%	12.3%	23.6%	9.6%
4.	Adjusted EBITDA ⁽¹⁾	1,889	1,792	1,533	6,793	5,622
5.	Adjusted EBITDA margin (%) ⁽¹⁾	18.8%	19.0%	20.3%	19.4%	19.8%
6.	Adjusted Profit after tax ⁽¹⁾	1,133	1,142	1,176	4,583	4,067
7.	Adjusted Profit margin (%) ⁽¹⁾	11.3%	12.1%	15.6%	13.1%	14.3%
8.	Cash Flow from Operating Activities	-	-	-	6,508	4,419

(1) Refer Earnings Presentation for details on Adjustments

“FY26 was a landmark year for Indegene. We surpassed ₹1,000 crore in quarterly revenue for the first time, and ₹3,500 crore for the full year”, said Manish Gupta, Chairman and CEO, Indegene. “This reflects growing strategic depth in our largest client relationships, with 53 clients contributing over \$1M in annual revenue, alongside breakthrough GenAI-led wins across Commercial and Medical. With a strong pipeline and an industry-leading revenue per employee of \$75k, we will build on this momentum in FY27.”

“FY26 reflected disciplined financial execution. Our cash conversion ratio of 162% reflects continued strong underlying cash generation, while higher non-cash charges impact the reported profits”, said Suhas Prabhu, CFO, Indegene. “Reflecting this strength, the Board has recommended a final dividend of ₹2.25 per share - a 12.5% increase over FY25. With healthy margins, strong cash generation, and recent acquisitions now integrated, we enter FY27 with confidence.”



About Indegene

Indegene Limited (BSE: 544172, NSE: INDGN) is the strategic operating partner to the global life sciences industry, orchestrating commercial, medical, R&D, and safety operations across the product lifecycle. Trusted by the world's top 20 biopharma companies, Indegene helps run complex, highly regulated workflows at global scale. Indegene combines deep life sciences expertise with AI-embedded platforms and governed operating models to improve speed, consistency, and compliance across mission-critical operations. By integrating technology into how work is executed and scaled, Indegene enables life sciences organizations to deliver measurable outcomes in regulated environments. For more information, visit www.indegene.com

For investor inquiries, please contact: IR@indegene.com

For media inquiries, please contact: yadunandan.kv@indegene.com